Details
Stereochemistry | RACEMIC |
Molecular Formula | C19H11BrF2N2O4 |
Molecular Weight | 449.202 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CC2=C(C=C1)C(=O)N(CC3=C(F)C=C(Br)C=C3)C(=O)C24CC(=O)NC4=O
InChI
InChIKey=BMHZAHGTGIZZCT-UHFFFAOYSA-N
InChI=1S/C19H11BrF2N2O4/c20-10-2-1-9(14(22)5-10)8-24-16(26)12-4-3-11(21)6-13(12)19(18(24)28)7-15(25)23-17(19)27/h1-6H,7-8H2,(H,23,25,27)
Molecular Formula | C19H11BrF2N2O4 |
Molecular Weight | 449.202 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Minalrestat was developed by Wyeth-Ayerst as an aldose reductase inhibitor. It is known, the aldose reductase inhibition might ameliorate diabetic complications through the correction of the altered microvascular reactivity by a mechanism that involves NO and membrane hyperpolarization. That is why minalrestat was studied for patients with diabetic retinopathy. However, Wyeth discontinued development of minalrestat.
Originator
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:54:36 GMT 2023
by
admin
on
Sat Dec 16 15:54:36 GMT 2023
|
Record UNII |
G44PE6QB31
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C72880
Created by
admin on Sat Dec 16 15:54:36 GMT 2023 , Edited by admin on Sat Dec 16 15:54:36 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL273910
Created by
admin on Sat Dec 16 15:54:36 GMT 2023 , Edited by admin on Sat Dec 16 15:54:36 GMT 2023
|
PRIMARY | |||
|
C72820
Created by
admin on Sat Dec 16 15:54:36 GMT 2023 , Edited by admin on Sat Dec 16 15:54:36 GMT 2023
|
PRIMARY | |||
|
100000080637
Created by
admin on Sat Dec 16 15:54:36 GMT 2023 , Edited by admin on Sat Dec 16 15:54:36 GMT 2023
|
PRIMARY | |||
|
190816
Created by
admin on Sat Dec 16 15:54:36 GMT 2023 , Edited by admin on Sat Dec 16 15:54:36 GMT 2023
|
PRIMARY | |||
|
SUB08972MIG
Created by
admin on Sat Dec 16 15:54:36 GMT 2023 , Edited by admin on Sat Dec 16 15:54:36 GMT 2023
|
PRIMARY | |||
|
7539
Created by
admin on Sat Dec 16 15:54:36 GMT 2023 , Edited by admin on Sat Dec 16 15:54:36 GMT 2023
|
PRIMARY | |||
|
DTXSID201021572
Created by
admin on Sat Dec 16 15:54:36 GMT 2023 , Edited by admin on Sat Dec 16 15:54:36 GMT 2023
|
PRIMARY | |||
|
II-18
Created by
admin on Sat Dec 16 15:54:36 GMT 2023 , Edited by admin on Sat Dec 16 15:54:36 GMT 2023
|
PRIMARY | |||
|
129688-50-2
Created by
admin on Sat Dec 16 15:54:36 GMT 2023 , Edited by admin on Sat Dec 16 15:54:36 GMT 2023
|
PRIMARY | |||
|
G44PE6QB31
Created by
admin on Sat Dec 16 15:54:36 GMT 2023 , Edited by admin on Sat Dec 16 15:54:36 GMT 2023
|
PRIMARY | |||
|
C473212
Created by
admin on Sat Dec 16 15:54:36 GMT 2023 , Edited by admin on Sat Dec 16 15:54:36 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
Discontinued : Diabetic retinopathy
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |